[Molybdocene dichloride as an antitumor agent (author's transl)].
The antitumor activity of molybdocene dichloride is tested against Ehrlich ascites tumor in CF1 mice. The application of 75 of 100 mg/kg 24 h after transplantation achieves 100% tumor inhibition until day 30. Following the d0 and d1 metallocene dichlorides of titanium and vanadium, molybdocene dichloride is the first analogous d2 system revealing similar antineoplastic properties.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D051379:Mice; D008982:Molybdenum / Q000627:therapeutic use*; D009942:Organometallic Compounds / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; C013108:metallocene; C024389:molybdocene dichloride; D008982:Molybdenum
Molybdocen-dichlorid als Antitumor-Agens.